Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women
The HPTN 084 study will evaluate injections given every two months
-
GSK submits US regulatory application for single-dose tafenoquine for Plasmodium vivax malaria
Regulatory milestone affirms GSK's strong commitment and scientific capabilities to fighting infectious diseases
-
GSK responds to UK Industrial Strategy
Read our response to the UK Industrial Strategy White Paper.
-
ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine
ViiV announced start of phase III study with a two-drug regimen of long-acting, injectable cabotegravir & rilpivirine in adults with HIV-1.
-
GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
-
Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
ViiV announced the FDA has approved Juluca®, complete regimen for the maintenance treatment of HIV-1 infection in virologically suppressed..
-
Trelegy Ellipta once-daily single inhaler triple therapy gains marketing authorisation in Europe for the treatment of COPD
GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta
-
GSK receives European marketing authorisation for self-injectable formulation of Benlysta for the treatment of systemic lupus erythematosus
The approval is for a single-dose prefilled syringe and a single-dose prefilled pen presentation, administered as a once weekly
-
Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK
Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK
-
First long-term efficacy analysis on the effect of GSK’s Benlysta on rate of organ damage progression in SLE versus standard therapy alone
GSK announced results of the first study assessing levels of organ damage in patients with active systemic lupus erythematosus (SLE)
-
Patrick Vallance, President, R&D, GSK to become UK Government's Chief Scientific Adviser
Patrick Vallance, President, R&D, GSK to become UK Government’s Chief Scientific Adviser
-
GSK submits US regulatory application for mepolizumab in eosinophilic chronic obstructive pulmonary disease (COPD)
GlaxoSmithKline plc today announced the submission of a supplemental Biologics License Application (sBLA) to the United States FDA
-
New multi-country survey reveals need for improved awareness around long-term impact and appropriate use of corticosteroids in SLE management
EnABLE highlight opportunity for increased awareness on appropriate corticosteroid use and a more proactive approach to management of SLE.
-
GSK’s investigational BCMA antibody-drug conjugate receives Breakthrough Therapy Designation from US FDA for relapsed and refractory multiple myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) announced it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration
-
GSK study demonstrates superiority of Anoro Ellipta to Stiolto Respimat in improving lung function in chronic obstructive pulmonary disease
GSK plc and Innoviva, Inc. announced positive data from a study
-
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV
ViiV Healthcare announced results from phase III BRIGHTE study of fostemsavir
-
Public-private consortium aims to cut preclinical cancer drug discovery from six years to just one
Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, GSK, and University of California San Francisco
-
CDC’s Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up
Committee recommends immunization for up to 62 million additional adults in the US
-
GSK delivers Q3 sales of £7.8 billion, +4% AER, +2% CER
Total EPS 24.8p, +49% AER, +46% CER; Adjusted EPS 32.5p, +3% AER, flat CER
-
Shingrix approved in the US for prevention of shingles in adults aged 50 and over
Pooled clinical trial results showed > 90 percent efficacy across all age groups
